Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study
In this nationwide study from the Israeli Inflammatory Bowel Disease Research Nucleus, we aimed to describe the incidence of very early onset inflammatory bowel diseases (VEOIBDs) with a focus on infantile-onset disease and to compare management and disease course with older children. Data were retr...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2023-09, Vol.21 (10), p.2639-2648.e6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2648.e6 |
|---|---|
| container_issue | 10 |
| container_start_page | 2639 |
| container_title | Clinical gastroenterology and hepatology |
| container_volume | 21 |
| creator | Atia, Ohad Benchimol, Eric I. Ledderman, Natan Greenfeld, Shira Kariv, Revital Weisband, Yiska Loewenberg Matz, Eran Ollech, Jacob Dotan, Iris Assa, Amit Shouval, Dror S. Uhlig, Holm H. Muise, Aleixo M. Olén, Ola Kuenzig, M. Ellen Kaplan, Gilaad G. Turner, Dan |
| description | In this nationwide study from the Israeli Inflammatory Bowel Disease Research Nucleus, we aimed to describe the incidence of very early onset inflammatory bowel diseases (VEOIBDs) with a focus on infantile-onset disease and to compare management and disease course with older children.
Data were retrieved from the 4 Israeli Health Maintenance Organizations covering 98% of the population. Pediatric-onset IBD was categorized as follows: adolescent onset (10 to |
| doi_str_mv | 10.1016/j.cgh.2022.10.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_449769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356522010151</els_id><sourcerecordid>2733200609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-bed747df2e70e3b4d1506e0a771dafe2070fcd0accee2fb0095a23e5e600daac3</originalsourceid><addsrcrecordid>eNqdUk1v1DAQtRCIloUfwAX5yKFZxnY-CJxK2UKkwkp8XS3HnhQvibONHaq99pfjKGnhAgdkSx7PvDcezzxCnjJYM2D5i91aX35fc-A83tfA83vkmGUpT4qCpfcXW2R5dkQeeb8D4GVaFg_JkchF3Iwfk5vKaWvQaTyhH5RTl9ihCydUOUO3Y9B9h572Df2Gw4Fu1NAe6NZ5DLRyTau6ToU-Bt7019jSt9aj8hE_kWNcuWBbTGb8EnxFTx3d7G1SVZ8-0s9hNIfH5EGjWo9PlnNFvp5vvpy9Ty6276qz04tEpyULSY2mSAvTcCwARZ0alkGOoOJfjWqQQwGNNqC0RuRNDVBmigvMMAcwSmmxIsmc11_jfqzlfrCdGg6yV1Yurh_RQpnGJuVlxJd_xe-H3vwm3RL5bV__gxtnBYV4GdeKPJ-5EXg1og-ys15j2yqH_eglL4TgADlMJbIZqofe-wGbu4cYyEkiciejROQkkckVJRI5z5b0Y92huWP8UfvrGYBxGD8tDtJrOynE2AF1kKa3_0j_CwlWzzc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2733200609</pqid></control><display><type>article</type><title>Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study</title><source>Access via ScienceDirect (Elsevier)</source><creator>Atia, Ohad ; Benchimol, Eric I. ; Ledderman, Natan ; Greenfeld, Shira ; Kariv, Revital ; Weisband, Yiska Loewenberg ; Matz, Eran ; Ollech, Jacob ; Dotan, Iris ; Assa, Amit ; Shouval, Dror S. ; Uhlig, Holm H. ; Muise, Aleixo M. ; Olén, Ola ; Kuenzig, M. Ellen ; Kaplan, Gilaad G. ; Turner, Dan</creator><creatorcontrib>Atia, Ohad ; Benchimol, Eric I. ; Ledderman, Natan ; Greenfeld, Shira ; Kariv, Revital ; Weisband, Yiska Loewenberg ; Matz, Eran ; Ollech, Jacob ; Dotan, Iris ; Assa, Amit ; Shouval, Dror S. ; Uhlig, Holm H. ; Muise, Aleixo M. ; Olén, Ola ; Kuenzig, M. Ellen ; Kaplan, Gilaad G. ; Turner, Dan</creatorcontrib><description><![CDATA[In this nationwide study from the Israeli Inflammatory Bowel Disease Research Nucleus, we aimed to describe the incidence of very early onset inflammatory bowel diseases (VEOIBDs) with a focus on infantile-onset disease and to compare management and disease course with older children.
Data were retrieved from the 4 Israeli Health Maintenance Organizations covering 98% of the population. Pediatric-onset IBD was categorized as follows: adolescent onset (10 to <18 y), early onset (6 to <10 y), VEOIBD (0 to <6 y), toddler onset (2 to <6 y), and infantile onset (<2 y).
A total of 5243 children with 35,469 person-years of follow-up evaluation, were diagnosed with IBD during 2005 to 2020: 4444 (85%) with adolescent onset, 548 (10%) with early onset, and 251 (4.8%) with VEOIBD, of whom 81 (1.5%) had infantile onset. The incidence of pediatric-onset IBD increased from 10.8 per 100,000 in 2005 to 15.3 per 100,000 in 2019 (average annual percentage change, 2.8%; 95% CI, 2.2%–3.4%), but that of VEOIBD remained stable (average annual percentage change, 0%; 95% CI, -2.5% to 2.6%). The infantile-onset and toddler-onset groups were treated less often with biologics (36% and 35%, respectively) vs the early onset (57%) and adolescent-onset groups (53%; P < .001). The time to steroid dependency was shorter in infantile-onset (hazard ratio [HR], 2.1; 95% CI, 1.5–2.9) and toddler-onset disease (HR, 1.6; 95% CI, 1.2–2.0) vs early onset and adolescent-onset disease, but time to hospitalizations, time to surgery, and growth delay were worse only in infantile-onset disease. In a multivariable model, infantile-onset patients had a higher risk for surgery (HR, 1.4; 95% CI, 1.1–1.9) and hospitalization (HR, 1.7; 95% CI, 1.2–2.4) than the toddler-onset group.
The incidence of VEOIBD remained stable. Infantile-onset IBD had worse outcomes than older children, while toddler onset had mostly similar outcomes, despite less frequent use of biologics.]]></description><identifier>ISSN: 1542-3565</identifier><identifier>ISSN: 1542-7714</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2022.10.026</identifier><identifier>PMID: 36336312</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>IBD ; Medicin och hälsovetenskap ; Outcomes ; Very Early Onset</subject><ispartof>Clinical gastroenterology and hepatology, 2023-09, Vol.21 (10), p.2639-2648.e6</ispartof><rights>2022 AGA Institute</rights><rights>Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-bed747df2e70e3b4d1506e0a771dafe2070fcd0accee2fb0095a23e5e600daac3</citedby><cites>FETCH-LOGICAL-c491t-bed747df2e70e3b4d1506e0a771dafe2070fcd0accee2fb0095a23e5e600daac3</cites><orcidid>0000-0001-7800-1984</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2022.10.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36336312$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:154073838$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:236336312$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Atia, Ohad</creatorcontrib><creatorcontrib>Benchimol, Eric I.</creatorcontrib><creatorcontrib>Ledderman, Natan</creatorcontrib><creatorcontrib>Greenfeld, Shira</creatorcontrib><creatorcontrib>Kariv, Revital</creatorcontrib><creatorcontrib>Weisband, Yiska Loewenberg</creatorcontrib><creatorcontrib>Matz, Eran</creatorcontrib><creatorcontrib>Ollech, Jacob</creatorcontrib><creatorcontrib>Dotan, Iris</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Shouval, Dror S.</creatorcontrib><creatorcontrib>Uhlig, Holm H.</creatorcontrib><creatorcontrib>Muise, Aleixo M.</creatorcontrib><creatorcontrib>Olén, Ola</creatorcontrib><creatorcontrib>Kuenzig, M. Ellen</creatorcontrib><creatorcontrib>Kaplan, Gilaad G.</creatorcontrib><creatorcontrib>Turner, Dan</creatorcontrib><title>Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description><![CDATA[In this nationwide study from the Israeli Inflammatory Bowel Disease Research Nucleus, we aimed to describe the incidence of very early onset inflammatory bowel diseases (VEOIBDs) with a focus on infantile-onset disease and to compare management and disease course with older children.
Data were retrieved from the 4 Israeli Health Maintenance Organizations covering 98% of the population. Pediatric-onset IBD was categorized as follows: adolescent onset (10 to <18 y), early onset (6 to <10 y), VEOIBD (0 to <6 y), toddler onset (2 to <6 y), and infantile onset (<2 y).
A total of 5243 children with 35,469 person-years of follow-up evaluation, were diagnosed with IBD during 2005 to 2020: 4444 (85%) with adolescent onset, 548 (10%) with early onset, and 251 (4.8%) with VEOIBD, of whom 81 (1.5%) had infantile onset. The incidence of pediatric-onset IBD increased from 10.8 per 100,000 in 2005 to 15.3 per 100,000 in 2019 (average annual percentage change, 2.8%; 95% CI, 2.2%–3.4%), but that of VEOIBD remained stable (average annual percentage change, 0%; 95% CI, -2.5% to 2.6%). The infantile-onset and toddler-onset groups were treated less often with biologics (36% and 35%, respectively) vs the early onset (57%) and adolescent-onset groups (53%; P < .001). The time to steroid dependency was shorter in infantile-onset (hazard ratio [HR], 2.1; 95% CI, 1.5–2.9) and toddler-onset disease (HR, 1.6; 95% CI, 1.2–2.0) vs early onset and adolescent-onset disease, but time to hospitalizations, time to surgery, and growth delay were worse only in infantile-onset disease. In a multivariable model, infantile-onset patients had a higher risk for surgery (HR, 1.4; 95% CI, 1.1–1.9) and hospitalization (HR, 1.7; 95% CI, 1.2–2.4) than the toddler-onset group.
The incidence of VEOIBD remained stable. Infantile-onset IBD had worse outcomes than older children, while toddler onset had mostly similar outcomes, despite less frequent use of biologics.]]></description><subject>IBD</subject><subject>Medicin och hälsovetenskap</subject><subject>Outcomes</subject><subject>Very Early Onset</subject><issn>1542-3565</issn><issn>1542-7714</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqdUk1v1DAQtRCIloUfwAX5yKFZxnY-CJxK2UKkwkp8XS3HnhQvibONHaq99pfjKGnhAgdkSx7PvDcezzxCnjJYM2D5i91aX35fc-A83tfA83vkmGUpT4qCpfcXW2R5dkQeeb8D4GVaFg_JkchF3Iwfk5vKaWvQaTyhH5RTl9ihCydUOUO3Y9B9h572Df2Gw4Fu1NAe6NZ5DLRyTau6ToU-Bt7019jSt9aj8hE_kWNcuWBbTGb8EnxFTx3d7G1SVZ8-0s9hNIfH5EGjWo9PlnNFvp5vvpy9Ty6276qz04tEpyULSY2mSAvTcCwARZ0alkGOoOJfjWqQQwGNNqC0RuRNDVBmigvMMAcwSmmxIsmc11_jfqzlfrCdGg6yV1Yurh_RQpnGJuVlxJd_xe-H3vwm3RL5bV__gxtnBYV4GdeKPJ-5EXg1og-ys15j2yqH_eglL4TgADlMJbIZqofe-wGbu4cYyEkiciejROQkkckVJRI5z5b0Y92huWP8UfvrGYBxGD8tDtJrOynE2AF1kKa3_0j_CwlWzzc</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Atia, Ohad</creator><creator>Benchimol, Eric I.</creator><creator>Ledderman, Natan</creator><creator>Greenfeld, Shira</creator><creator>Kariv, Revital</creator><creator>Weisband, Yiska Loewenberg</creator><creator>Matz, Eran</creator><creator>Ollech, Jacob</creator><creator>Dotan, Iris</creator><creator>Assa, Amit</creator><creator>Shouval, Dror S.</creator><creator>Uhlig, Holm H.</creator><creator>Muise, Aleixo M.</creator><creator>Olén, Ola</creator><creator>Kuenzig, M. Ellen</creator><creator>Kaplan, Gilaad G.</creator><creator>Turner, Dan</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0001-7800-1984</orcidid></search><sort><creationdate>20230901</creationdate><title>Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study</title><author>Atia, Ohad ; Benchimol, Eric I. ; Ledderman, Natan ; Greenfeld, Shira ; Kariv, Revital ; Weisband, Yiska Loewenberg ; Matz, Eran ; Ollech, Jacob ; Dotan, Iris ; Assa, Amit ; Shouval, Dror S. ; Uhlig, Holm H. ; Muise, Aleixo M. ; Olén, Ola ; Kuenzig, M. Ellen ; Kaplan, Gilaad G. ; Turner, Dan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-bed747df2e70e3b4d1506e0a771dafe2070fcd0accee2fb0095a23e5e600daac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>IBD</topic><topic>Medicin och hälsovetenskap</topic><topic>Outcomes</topic><topic>Very Early Onset</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atia, Ohad</creatorcontrib><creatorcontrib>Benchimol, Eric I.</creatorcontrib><creatorcontrib>Ledderman, Natan</creatorcontrib><creatorcontrib>Greenfeld, Shira</creatorcontrib><creatorcontrib>Kariv, Revital</creatorcontrib><creatorcontrib>Weisband, Yiska Loewenberg</creatorcontrib><creatorcontrib>Matz, Eran</creatorcontrib><creatorcontrib>Ollech, Jacob</creatorcontrib><creatorcontrib>Dotan, Iris</creatorcontrib><creatorcontrib>Assa, Amit</creatorcontrib><creatorcontrib>Shouval, Dror S.</creatorcontrib><creatorcontrib>Uhlig, Holm H.</creatorcontrib><creatorcontrib>Muise, Aleixo M.</creatorcontrib><creatorcontrib>Olén, Ola</creatorcontrib><creatorcontrib>Kuenzig, M. Ellen</creatorcontrib><creatorcontrib>Kaplan, Gilaad G.</creatorcontrib><creatorcontrib>Turner, Dan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atia, Ohad</au><au>Benchimol, Eric I.</au><au>Ledderman, Natan</au><au>Greenfeld, Shira</au><au>Kariv, Revital</au><au>Weisband, Yiska Loewenberg</au><au>Matz, Eran</au><au>Ollech, Jacob</au><au>Dotan, Iris</au><au>Assa, Amit</au><au>Shouval, Dror S.</au><au>Uhlig, Holm H.</au><au>Muise, Aleixo M.</au><au>Olén, Ola</au><au>Kuenzig, M. Ellen</au><au>Kaplan, Gilaad G.</au><au>Turner, Dan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>21</volume><issue>10</issue><spage>2639</spage><epage>2648.e6</epage><pages>2639-2648.e6</pages><issn>1542-3565</issn><issn>1542-7714</issn><eissn>1542-7714</eissn><abstract><![CDATA[In this nationwide study from the Israeli Inflammatory Bowel Disease Research Nucleus, we aimed to describe the incidence of very early onset inflammatory bowel diseases (VEOIBDs) with a focus on infantile-onset disease and to compare management and disease course with older children.
Data were retrieved from the 4 Israeli Health Maintenance Organizations covering 98% of the population. Pediatric-onset IBD was categorized as follows: adolescent onset (10 to <18 y), early onset (6 to <10 y), VEOIBD (0 to <6 y), toddler onset (2 to <6 y), and infantile onset (<2 y).
A total of 5243 children with 35,469 person-years of follow-up evaluation, were diagnosed with IBD during 2005 to 2020: 4444 (85%) with adolescent onset, 548 (10%) with early onset, and 251 (4.8%) with VEOIBD, of whom 81 (1.5%) had infantile onset. The incidence of pediatric-onset IBD increased from 10.8 per 100,000 in 2005 to 15.3 per 100,000 in 2019 (average annual percentage change, 2.8%; 95% CI, 2.2%–3.4%), but that of VEOIBD remained stable (average annual percentage change, 0%; 95% CI, -2.5% to 2.6%). The infantile-onset and toddler-onset groups were treated less often with biologics (36% and 35%, respectively) vs the early onset (57%) and adolescent-onset groups (53%; P < .001). The time to steroid dependency was shorter in infantile-onset (hazard ratio [HR], 2.1; 95% CI, 1.5–2.9) and toddler-onset disease (HR, 1.6; 95% CI, 1.2–2.0) vs early onset and adolescent-onset disease, but time to hospitalizations, time to surgery, and growth delay were worse only in infantile-onset disease. In a multivariable model, infantile-onset patients had a higher risk for surgery (HR, 1.4; 95% CI, 1.1–1.9) and hospitalization (HR, 1.7; 95% CI, 1.2–2.4) than the toddler-onset group.
The incidence of VEOIBD remained stable. Infantile-onset IBD had worse outcomes than older children, while toddler onset had mostly similar outcomes, despite less frequent use of biologics.]]></abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36336312</pmid><doi>10.1016/j.cgh.2022.10.026</doi><orcidid>https://orcid.org/0000-0001-7800-1984</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-3565 |
| ispartof | Clinical gastroenterology and hepatology, 2023-09, Vol.21 (10), p.2639-2648.e6 |
| issn | 1542-3565 1542-7714 1542-7714 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_449769 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | IBD Medicin och hälsovetenskap Outcomes Very Early Onset |
| title | Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T13%3A35%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence,%20Management,%20and%20Outcomes%20of%20Very%20Early%20Onset%20Inflammatory%20Bowel%20Diseases%20and%20Infantile-Onset%20Disease:%20An%20Epi-IIRN%20Study&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Atia,%20Ohad&rft.date=2023-09-01&rft.volume=21&rft.issue=10&rft.spage=2639&rft.epage=2648.e6&rft.pages=2639-2648.e6&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2022.10.026&rft_dat=%3Cproquest_swepu%3E2733200609%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2733200609&rft_id=info:pmid/36336312&rft_els_id=S1542356522010151&rfr_iscdi=true |